Developer docs
API playgroundTry for free, no card

Search company profiles

Generium

Full company profile

uuid000d93x

Namestring
Generium
Legal namestring
АО «ГЕНЕРИУМ» (Joint Stock Company GENERIUM)
Websiteurl
generium.ru
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Generium is a Russian full-cycle biopharmaceutical company founded in 2008 and headquartered in Moscow, operating an integrated biotechnopark in Volginsky (Vladimir Region) that combines a research institute, preclinical and clinical trial capabilities, and high-tech manufacturing. The company develops both biosimilars and original innovative drugs using recombinant DNA technology, CHO cell lines, and advanced therapy platforms including gene therapy (AAV9 vectors) and oligonucleotide synthesis. Its marketed portfolio spans orphan diseases (MPS II/VI, SMA, Gaucher, PNH), autoimmune conditions (rheumatoid arthritis, psoriasis, multiple sclerosis), oncology, cardiovascular (thrombolytics), and ophthalmology, with several products described as world's first biosimilars or original therapies — notably Clotilia (verenafusp alfa), the first approved drug to use insulin receptor-mediated transcytosis to cross the blood-brain barrier for Hunter syndrome. The company also produces diagnostic medical equipment (SCREENSPOT ELISPOT analyzer for tuberculosis) and operates a pipeline of 30+ medications in development.

Generium distributes products entirely through Russian state healthcare channels: federal and regional government procurement, the Circle of Goodness Foundation (an exclusive supplier relationship for SMA and other orphan disease funding), direct hospital/clinic supply, and open tenders. Pricing is set via government procurement rather than commercial channels, and select products (e.g., Vapromin/risdiplam) are listed on the ЖНВЛП (vital and essential drugs) list. The company employs 1,900+ personnel across 8,000 m² of laboratory space and 61,000 m² of production facilities, and in October 2025 opened the Generium-Next plant in the Alabushevo special economic zone (Moscow), adding 28,000+ m² and capacity for 5.4 million vials per year. International activity is nascent, limited to a clinical trial site in Belarus for GNR-097 gene therapy in Duchenne muscular dystrophy.

Short descriptiontext

Generium is a Russian full-cycle biopharmaceutical company that develops biosimilars and innovative drugs for orphan, autoimmune, oncological, and cardiovascular diseases, distributing entirely through Russian state healthcare procurement and the Circle of Goodness Foundation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMoscow, Russia
HQ citystring
Moscow
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical manufacturing, biosimilar development, orphan disease therapies, gene therapy drugs, recombinant protein production
Industry4 codes
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Manufacturing (Biosimilars and Gene Therapy)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of biopharmaceutical drugs including biosimilars, generics, and innovative therapies for orphan diseases, oncology, and autoimmune conditions. Products are supplied to Russian healthcare institutions through government procurement and the Circle of Goodness Foundation.

generium.ru
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Generium is a full-cycle Russian biotechnology company that researches, develops, and manufactures genetically engineered biopharmaceutical products. It produces biosimilars and original biologics — including monoclonal antibodies, enzymes, antisense oligonucleotides, coagulation factors, and gene therapies — for orphan diseases (MPS II, MPS VI, SMA, Gaucher, PNH, aHUS), autoimmune conditions, oncology, cardiovascular disease, and ophthalmology, distributed primarily to Russian government healthcare programs and hospitals. It also operates a domestic microplate analyzer (SCREENSPOT) and TB diagnostic reagent system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Over 200 injections of Lantesens® administered to patients with spinal muscular atrophy across dozens of Russian regions
+6 more records
Product overview1 text field

Generium is a Russian innovative biotechnology company operating as an integrated biotechnopark that combines a world-class research institute, preclinical and clinical trial control centers, and high-tech manufacturing facilities. The company's product portfolio spans multiple categories: (1) pharmaceutical products including biosimilars and original drugs for orphan diseases (MPS II, MPS VI, SMA, Gaucher disease), autoimmune conditions (rheumatoid arthritis, psoriasis, multiple sclerosis), oncology, and cardiovascular diseases (thrombolytics); (2) diagnostic systems including the SCREENSPOT microplate analyzer for tuberculosis testing and TigraTest TB reagent kits; and (3) a robust pipeline of gene therapies and biosimilars in development. Manufacturing capabilities include blood coagulation factors, cytokines, antibodies, enzymes, allergens, and ATMPs (Advanced Therapy Medicinal Products). The company operates from facilities in Volginsky (Vladimir Region) and Alabushevo (Moscow Special Economic Zone), producing approximately 5.4 million vials annually.

Product and service22 records
1Clotilia® (verenafusp alfa)
CategoryOrphan disease biologic (Hunter syndrome)
Description

Original innovative biologic for Hunter syndrome (MPS II) that crosses the blood-brain barrier via insulin-receptor-mediated transcytosis, delivering iduronate-2-sulfatase directly to the central nervous system. Indicated for patients aged 6+ with Hunter syndrome.

2Readeli® (galsulfase)
CategoryOrphan disease biologic (MPS VI)
Description

Biosimilar of recombinant N-acetylgalactosamine-4-sulfatase (galsulfase) for enzyme replacement therapy in patients with Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome). Restores enzyme activity to hydrolyze accumulated dermatan sulfate.

3Elizaria® (eculizumab biosimilar)
CategoryOrphan disease biologic (PNH/aHUS)
Description

Biosimilar of eculizumab, a humanized monoclonal antibody that binds complement protein C5. Indicated for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). 50 patients with aHUS received Elizaria® through an early-access program, including 26 children saved from death.

4Lantesens® (nusinersen)
CategoryOrphan disease biologic (SMA)
Description

First Russian-developed generic nusinersen — an antisense oligonucleotide that increases survival motor neuron (SMN) protein levels to prevent disease progression in spinal muscular atrophy (5q SMA). Over 200 injections have been administered across dozens of Russian regions.

5Glurazyme® (imiglucerase biosimilar)
CategoryOrphan disease biologic (Gaucher disease)
Description

Biosimilar of recombinant beta-glucocerebrosidase (imiglucerase) for enzyme replacement therapy in patients with Gaucher disease types 1 and 3. The only Russian company producing an imiglucerase biosimilar.

6Complarate® (tocilizumab biosimilar)
CategoryAutoimmune biologic (IL-6 inhibitor)
Description

First Russian-registered biosimilar of tocilizumab, a humanized monoclonal antibody binding the IL-6 receptor. Indicated for rheumatoid arthritis, systemic juvenile idiopathic arthritis, severe COVID-19, and cytokine release syndrome.

7Styleikin® (ustekinumab biosimilar)
CategoryAutoimmune biologic (IL-12/IL-23 inhibitor)
Description

First Russian-developed biosimilar of ustekinumab — a fully human monoclonal antibody targeting IL-12 and IL-23 — for plaque psoriasis and psoriatic arthritis in adults and children.

8Limiris® (canakinumab biosimilar)
CategoryAutoimmune biologic (IL-1β inhibitor)
Description

First Russian-developed biosimilar of canakinumab — a human monoclonal antibody targeting interleukin-1β — for autoinflammatory fever syndromes, Still's disease, systemic juvenile idiopathic arthritis, and gouty arthritis.

9Tigerase® (dornase alfa biosimilar)
CategoryOrphan/respiratory biologic (cystic fibrosis)
Description

First-in-the-world biosimilar of recombinant human deoxyribonuclease I (dornase alfa), which cleaves extracellular DNA in bronchial secretions to improve lung function in patients with cystic fibrosis.

10Continia® (aflibercept biosimilar)
CategoryOphthalmology biologic (anti-VEGF)
Description

First Russian-developed biosimilar of aflibercept — a recombinant fusion protein inhibiting VEGF — for ophthalmic diseases including wet AMD, diabetic macular edema, retinal vein occlusion macular edema, and myopic choroidal neovascularization.

11Laxolan® (ranibizumab biosimilar)
CategoryOphthalmology biologic (anti-VEGF)
Description

Biosimilar of ranibizumab — a non-glycosylated recombinant antibody fragment targeting VEGF-A — for wet AMD, diabetic macular edema, proliferative diabetic retinopathy, macular edema from retinal vein occlusion, and choroidal neovascularization.

12Vapromin® (risdiplam)
CategoryOrphan disease small molecule (SMA)
Description

Risdiplam — an SMN2 splicing modifier — for the treatment of spinal muscular atrophy. Included in the Russian list of vital and essential medicines (ЖНВЛП).

13Koagil-VII® (eptacog alfa [activated])
CategoryHematology biologic (coagulation factor)
Description

Eptacog alfa [activated] — recombinant activated factor VII identical to human factor VIIa. Universal hemostatic agent for hemophilia with inhibitors, acquired hemophilia, factor VII deficiency, Glanzmann thrombasthenia, and postpartum hemorrhage.

14Genolair® (omalizumab biosimilar)
CategoryRespiratory/immunology biologic (anti-IgE)
Description

Omalizumab biosimilar — an anti-IgE monoclonal antibody — for allergic asthma and chronic idiopathic urticaria. Marketed in both lyophilizate and solution dosage forms.

15Nekteliza® (tenecteplase biosimilar)
CategoryCardiovascular biologic (thrombolytic)
Description

Biosimilar of tenecteplase — a fibrin-specific plasminogen activator — for thrombolytic therapy of acute myocardial infarction and ischemic stroke in adults, administered as a single bolus injection.

16Reveliza® (alteplase biosimilar)
CategoryCardiovascular biologic (thrombolytic)
Description

Biosimilar of alteplase — tissue plasminogen activator — for thrombolytic therapy.

17Efiktel® (natalizumab biosimilar)
CategoryAutoimmune biologic (multiple sclerosis)
Description

Biosimilar of natalizumab — a monoclonal antibody targeting α4-integrin — for relapsing forms of multiple sclerosis and Crohn's disease.

18Infibeta® (interferon beta-1b)
CategoryAutoimmune biologic (multiple sclerosis)
Description

Recombinant interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.

19Stimplate® (romiplostim biosimilar)
CategoryHematology biologic
Description

Romiplostim biosimilar — a thrombopoietin receptor agonist — for the treatment of immune thrombocytopenia.

20SCREENSPOT microplate analyzer
CategoryIn vitro diagnostic medical device
Description

Medical device — a Russian-developed microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. Production capacity up to 300 units per year via the Troitsk Engineering Center partnership.

21TigraTest TB reagent kit
CategoryIn vitro diagnostic reagent
Description

Test system for tuberculosis diagnosis using the ELISPOT method to assess cellular immunity (IGRA methodology). Used with the SCREENSPOT analyzer in clinical diagnostic laboratories.

22GNR-097 (Duchenne muscular dystrophy gene therapy)
CategoryPipeline gene therapy (DMD)
Description

Gene therapy drug for Duchenne muscular dystrophy using a recombinant adeno-associated viral vector of serotype 9 encoding a truncated dystrophin gene. Currently in Phase 1/2 multicenter clinical trial in boys aged 4-9 in Russia and Belarus.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Full-cycle project for SCREENSPOT microplate analyzer development. Troitsk Engineering Center engineers collaborated with Generium biotechnologists. Software-hardware complex and reagents are entirely Russian development. The Troitsk Engineering Center produces SCREENSPOT analyzers with capacity up to 300 units per year.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Launch of production for Sputnik V COVID-19 vaccine as part of Russia's vaccination campaign.

3SG Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

Joint venture established in 2008 for biotechnological development and production activities.

generium.ru
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific research is conducted jointly with biotechnology companies and scientific institutes from around the world. No specific named partners listed.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

India's leading biosimilar manufacturer (trastuzumab, bevacizumab, insulin glargine) with global commercialization partnerships. Closely comparable to Generium in business model: biosimilar-led biologics manufacturer with growing novel biologics pipeline.

TypeDirect peer
Description

Russia's largest domestic biotechnology company developing biosimilars (rituximab, bevacizumab, adalimumab, etanercept, trastuzumab) and innovative biologics. Direct competitor to Generium in the Russian orphan, autoimmune, and oncology biosimilar segments with overlapping government procurement exposure.

TypeBroad incumbent
Description

Korea's largest biosimilar developer (infliximab, rituximab, trastuzumab, bevacizumab) with vertical manufacturing. Comparable to Generium's biosimilar strategy and full-cycle development approach.

TypeEmerging player
Description

Samsung-Biogen joint venture developing biosimilars of etanercept, infliximab, adalimumab, ranibizumab and others. Comparable to Generium's biosimilar pipeline breadth and monoclonal antibody manufacturing capabilities.

TypeDirect peer
Description

Major Russian pharmaceutical and biotechnology company with branded generics, biosimilars, and contract manufacturing. Competes with Generium for Russian government tenders, healthcare procurement, and talent in the biologics space.

TypeBroad incumbent
Description

European specialty pharma and biosimilar company focused on generics, biosimilars (including teriparatide, pegfilgrastim, adalimumab), and consumer health. Comparable diversified biosimilar portfolio and emerging-markets manufacturing footprint.

TypeBroad incumbent
Description

Largest Russian pharmaceutical manufacturer by volume with a broad branded generics and OTC portfolio. Overlaps with Generium in state drug procurement programs and serves as a benchmark for domestic pharma scale in Russia.

TypeRegional player
Description

Polish biosimilars developer and CDMO with WHO-GMP manufacturing facilities across Europe. Comparable to Generium as a mid-size European/CIS biosimilar manufacturer focused on monoclonal antibodies and recombinant proteins for global markets.

TypeEmerging player
Description

Icelandic biosimilar specialist developing adalimumab, ustekinumab, aflibercept, and other biosimilars. Comparable to Generium in targeting biosimilars of complex biologics including monoclonal antibodies and recombinant enzymes, with vertically integrated manufacturing.

TypeDirect peer
Description

U.S. gene therapy leader for Duchenne muscular dystrophy with ELEVIDYS (delandistrogene moxeparvovec), an AAV-based therapy. Direct therapeutic competitor to Generium's GNR-097 AAV9-microdystrophin program in DMD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Generium

Biopharmaceutical Manufacturing (Biosimilars and Gene Therapy)generium.ru

Generium is a Russian full-cycle biopharmaceutical company that develops biosimilars and innovative drugs for orphan, autoimmune, oncological, and cardiovascular diseases, distributing entirely through Russian state healthcare procurement and the Circle of Goodness Foundation.

What Generium does

Generium is a Russian full-cycle biopharmaceutical company founded in 2008 and headquartered in Moscow, operating an integrated biotechnopark in Volginsky (Vladimir Region) that combines a research institute, preclinical and clinical trial capabilities, and high-tech manufacturing. The company develops both biosimilars and original innovative drugs using recombinant DNA technology, CHO cell lines, and advanced therapy platforms including gene therapy (AAV9 vectors) and oligonucleotide synthesis. Its marketed portfolio spans orphan diseases (MPS II/VI, SMA, Gaucher, PNH), autoimmune conditions (rheumatoid arthritis, psoriasis, multiple sclerosis), oncology, cardiovascular (thrombolytics), and ophthalmology, with several products described as world's first biosimilars or original therapies — notably Clotilia (verenafusp alfa), the first approved drug to use insulin receptor-mediated transcytosis to cross the blood-brain barrier for Hunter syndrome. The company also produces diagnostic medical equipment (SCREENSPOT ELISPOT analyzer for tuberculosis) and operates a pipeline of 30+ medications in development.

Generium distributes products entirely through Russian state healthcare channels: federal and regional government procurement, the Circle of Goodness Foundation (an exclusive supplier relationship for SMA and other orphan disease funding), direct hospital/clinic supply, and open tenders. Pricing is set via government procurement rather than commercial channels, and select products (e.g., Vapromin/risdiplam) are listed on the ЖНВЛП (vital and essential drugs) list. The company employs 1,900+ personnel across 8,000 m² of laboratory space and 61,000 m² of production facilities, and in October 2025 opened the Generium-Next plant in the Alabushevo special economic zone (Moscow), adding 28,000+ m² and capacity for 5.4 million vials per year. International activity is nascent, limited to a clinical trial site in Belarus for GNR-097 gene therapy in Duchenne muscular dystrophy.

Generium firmographics

Firmographics
Name
Generium
Legal name
АО «ГЕНЕРИУМ» (Joint Stock Company GENERIUM)
Website
https://generium.ru
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Short description
Generium is a Russian full-cycle biopharmaceutical company that develops biosimilars and innovative drugs for orphan, autoimmune, oncological, and cardiovascular diseases, distributing entirely through Russian state healthcare procurement and the Circle of Goodness Foundation.
Ownership category
akta.pro rank

Generium industry classification

Industry
Product category
Biopharmaceutical Manufacturing (Biosimilars and Gene Therapy)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Biopharmaceutical manufacturing
  • Biosimilar development
  • Orphan disease therapies
  • Gene therapy drugs
  • Recombinant protein production

Where Generium is headquartered

Location

Headquarters

HQ city
Moscow
HQ country
Russia
HQ region
Europe

Offices5 records

Markets served

Generium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of biopharmaceutical drugs including biosimilars, generics, and innovative therapies for orphan diseases, oncology, and autoimmune conditions. Products are supplied to Russian healthcare institutions through government procurement and the Circle of Goodness Foundation.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Generium product offering

Product offering

Core offering

Generium is a full-cycle Russian biotechnology company that researches, develops, and manufactures genetically engineered biopharmaceutical products. It produces biosimilars and original biologics — including monoclonal antibodies, enzymes, antisense oligonucleotides, coagulation factors, and gene therapies — for orphan diseases (MPS II, MPS VI, SMA, Gaucher, PNH, aHUS), autoimmune conditions, oncology, cardiovascular disease, and ophthalmology, distributed primarily to Russian government healthcare programs and hospitals. It also operates a domestic microplate analyzer (SCREENSPOT) and TB diagnostic reagent system.

Product overview

Generium is a Russian innovative biotechnology company operating as an integrated biotechnopark that combines a world-class research institute, preclinical and clinical trial control centers, and high-tech manufacturing facilities. The company's product portfolio spans multiple categories: (1) pharmaceutical products including biosimilars and original drugs for orphan diseases (MPS II, MPS VI, SMA, Gaucher disease), autoimmune conditions (rheumatoid arthritis, psoriasis, multiple sclerosis), oncology, and cardiovascular diseases (thrombolytics); (2) diagnostic systems including the SCREENSPOT microplate analyzer for tuberculosis testing and TigraTest TB reagent kits; and (3) a robust pipeline of gene therapies and biosimilars in development. Manufacturing capabilities include blood coagulation factors, cytokines, antibodies, enzymes, allergens, and ATMPs (Advanced Therapy Medicinal Products). The company operates from facilities in Volginsky (Vladimir Region) and Alabushevo (Moscow Special Economic Zone), producing approximately 5.4 million vials annually.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clotilia® (verenafusp alfa) Original innovative biologic for Hunter syndrome (MPS II) that crosses the blood-brain barrier via insulin-receptor-mediated transcytosis, delivering iduronate-2-sulfatase directly to the central nervous system. Indicated for patients aged 6+ with Hunter syndrome.
  • Readeli® (galsulfase) Biosimilar of recombinant N-acetylgalactosamine-4-sulfatase (galsulfase) for enzyme replacement therapy in patients with Mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome). Restores enzyme activity to hydrolyze accumulated dermatan sulfate.
  • Elizaria® (eculizumab biosimilar) Biosimilar of eculizumab, a humanized monoclonal antibody that binds complement protein C5. Indicated for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). 50 patients with aHUS received Elizaria® through an early-access program, including 26 children saved from death.
  • Lantesens® (nusinersen) First Russian-developed generic nusinersen — an antisense oligonucleotide that increases survival motor neuron (SMN) protein levels to prevent disease progression in spinal muscular atrophy (5q SMA). Over 200 injections have been administered across dozens of Russian regions.
  • Glurazyme® (imiglucerase biosimilar) Biosimilar of recombinant beta-glucocerebrosidase (imiglucerase) for enzyme replacement therapy in patients with Gaucher disease types 1 and 3. The only Russian company producing an imiglucerase biosimilar.
  • Complarate® (tocilizumab biosimilar) First Russian-registered biosimilar of tocilizumab, a humanized monoclonal antibody binding the IL-6 receptor. Indicated for rheumatoid arthritis, systemic juvenile idiopathic arthritis, severe COVID-19, and cytokine release syndrome.
  • Styleikin® (ustekinumab biosimilar) First Russian-developed biosimilar of ustekinumab — a fully human monoclonal antibody targeting IL-12 and IL-23 — for plaque psoriasis and psoriatic arthritis in adults and children.
  • Limiris® (canakinumab biosimilar) First Russian-developed biosimilar of canakinumab — a human monoclonal antibody targeting interleukin-1β — for autoinflammatory fever syndromes, Still's disease, systemic juvenile idiopathic arthritis, and gouty arthritis.
  • Tigerase® (dornase alfa biosimilar) First-in-the-world biosimilar of recombinant human deoxyribonuclease I (dornase alfa), which cleaves extracellular DNA in bronchial secretions to improve lung function in patients with cystic fibrosis.
  • Continia® (aflibercept biosimilar) First Russian-developed biosimilar of aflibercept — a recombinant fusion protein inhibiting VEGF — for ophthalmic diseases including wet AMD, diabetic macular edema, retinal vein occlusion macular edema, and myopic choroidal neovascularization.
  • Laxolan® (ranibizumab biosimilar) Biosimilar of ranibizumab — a non-glycosylated recombinant antibody fragment targeting VEGF-A — for wet AMD, diabetic macular edema, proliferative diabetic retinopathy, macular edema from retinal vein occlusion, and choroidal neovascularization.
  • Vapromin® (risdiplam) Risdiplam — an SMN2 splicing modifier — for the treatment of spinal muscular atrophy. Included in the Russian list of vital and essential medicines (ЖНВЛП).
  • Koagil-VII® (eptacog alfa [activated]) Eptacog alfa [activated] — recombinant activated factor VII identical to human factor VIIa. Universal hemostatic agent for hemophilia with inhibitors, acquired hemophilia, factor VII deficiency, Glanzmann thrombasthenia, and postpartum hemorrhage.
  • Genolair® (omalizumab biosimilar) Omalizumab biosimilar — an anti-IgE monoclonal antibody — for allergic asthma and chronic idiopathic urticaria. Marketed in both lyophilizate and solution dosage forms.
  • Nekteliza® (tenecteplase biosimilar) Biosimilar of tenecteplase — a fibrin-specific plasminogen activator — for thrombolytic therapy of acute myocardial infarction and ischemic stroke in adults, administered as a single bolus injection.
  • Reveliza® (alteplase biosimilar) Biosimilar of alteplase — tissue plasminogen activator — for thrombolytic therapy.
  • Efiktel® (natalizumab biosimilar) Biosimilar of natalizumab — a monoclonal antibody targeting α4-integrin — for relapsing forms of multiple sclerosis and Crohn's disease.
  • Infibeta® (interferon beta-1b) Recombinant interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.
  • Stimplate® (romiplostim biosimilar) Romiplostim biosimilar — a thrombopoietin receptor agonist — for the treatment of immune thrombocytopenia.
  • SCREENSPOT microplate analyzer Medical device — a Russian-developed microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. Production capacity up to 300 units per year via the Troitsk Engineering Center partnership.
  • TigraTest TB reagent kit Test system for tuberculosis diagnosis using the ELISPOT method to assess cellular immunity (IGRA methodology). Used with the SCREENSPOT analyzer in clinical diagnostic laboratories.
  • GNR-097 (Duchenne muscular dystrophy gene therapy) Gene therapy drug for Duchenne muscular dystrophy using a recombinant adeno-associated viral vector of serotype 9 encoding a truncated dystrophin gene. Currently in Phase 1/2 multicenter clinical trial in boys aged 4-9 in Russia and Belarus.

Quantifiable outcome

  • Over 200 injections of Lantesens® administered to patients with spinal muscular atrophy across dozens of Russian regions
  • +6 more outcomes

Companies that use Generium

Customer profile

Named customers10 records

Segments6 records

Ideal customer profiles3 records

Generium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Generium partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Troitsk Engineering CentercoreStrategic or Co-development Partner · 1 January 2025Full-cycle project for SCREENSPOT microplate analyzer development. Troitsk Engineering Center engineers collaborated with Generium biotechnologists. Software-hardware complex and reagents are entirely Russian development. The Troitsk Engineering Center produces SCREENSPOT analyzers with capacity up to 300 units per year.
  • Sputnik V ProductionminorStrategic or Co-development Partner · 1 January 2021Launch of production for Sputnik V COVID-19 vaccine as part of Russia's vaccination campaign.
  • SG BiotechcoreStrategic or Co-development Partner · 1 January 2008Joint venture established in 2008 for biotechnological development and production activities.
  • Global Biotechnology Companies and Research InstitutesminorStrategic or Co-development PartnerScientific research is conducted jointly with biotechnology companies and scientific institutes from around the world. No specific named partners listed.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Generium competitors and assessment

Company assessment

Broad incumbents

  • Biocon: India's leading biosimilar manufacturer (trastuzumab, bevacizumab, insulin glargine) with global commercialization partnerships. Closely comparable to Generium in business model: biosimilar-led biologics manufacturer with growing novel biologics pipeline.
  • Celltrion: Korea's largest biosimilar developer (infliximab, rituximab, trastuzumab, bevacizumab) with vertical manufacturing. Comparable to Generium's biosimilar strategy and full-cycle development approach.
  • Stada Arzneimittel: European specialty pharma and biosimilar company focused on generics, biosimilars (including teriparatide, pegfilgrastim, adalimumab), and consumer health. Comparable diversified biosimilar portfolio and emerging-markets manufacturing footprint.
  • Pharmstandard: Largest Russian pharmaceutical manufacturer by volume with a broad branded generics and OTC portfolio. Overlaps with Generium in state drug procurement programs and serves as a benchmark for domestic pharma scale in Russia.

Direct peers

  • BIOCAD: Russia's largest domestic biotechnology company developing biosimilars (rituximab, bevacizumab, adalimumab, etanercept, trastuzumab) and innovative biologics. Direct competitor to Generium in the Russian orphan, autoimmune, and oncology biosimilar segments with overlapping government procurement exposure.
  • R-Pharm: Major Russian pharmaceutical and biotechnology company with branded generics, biosimilars, and contract manufacturing. Competes with Generium for Russian government tenders, healthcare procurement, and talent in the biologics space.
  • Sarepta Therapeutics: U.S. gene therapy leader for Duchenne muscular dystrophy with ELEVIDYS (delandistrogene moxeparvovec), an AAV-based therapy. Direct therapeutic competitor to Generium's GNR-097 AAV9-microdystrophin program in DMD.

Emerging players

  • Samsung Bioepis: Samsung-Biogen joint venture developing biosimilars of etanercept, infliximab, adalimumab, ranibizumab and others. Comparable to Generium's biosimilar pipeline breadth and monoclonal antibody manufacturing capabilities.
  • Alvotech: Icelandic biosimilar specialist developing adalimumab, ustekinumab, aflibercept, and other biosimilars. Comparable to Generium in targeting biosimilars of complex biologics including monoclonal antibodies and recombinant enzymes, with vertically integrated manufacturing.

Regional players

  • Polpharma Biologics: Polish biosimilars developer and CDMO with WHO-GMP manufacturing facilities across Europe. Comparable to Generium as a mid-size European/CIS biosimilar manufacturer focused on monoclonal antibodies and recombinant proteins for global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Generium social profiles

Digital presence

Generium compliance and trust

Trust signal

Compliance4 records

Generium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Generium leadership team

Management profile

Number of profiles

Profiles3 records

Generium subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Generium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Generium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Generium

What does Generium do?

Generium is a full-cycle Russian biotechnology company that researches, develops, and manufactures genetically engineered biopharmaceutical products. It produces biosimilars and original biologics — including monoclonal antibodies, enzymes, antisense oligonucleotides, coagulation factors, and gene therapies — for orphan diseases (MPS II, MPS VI, SMA, Gaucher, PNH, aHUS), autoimmune conditions, oncology, cardiovascular disease, and ophthalmology, distributed primarily to Russian government healthcare programs and hospitals. It also operates a domestic microplate analyzer (SCREENSPOT) and TB diagnostic reagent system.

Is Generium a public or private company?

Generium is a private company. It is classified as unknown and is currently operating.

When was Generium founded?

Generium was founded in 2008. It employs 101 to 250 people.

Where is Generium based?

Generium is headquartered in Moscow, Russia, in the Europe region.

How does Generium make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Generium's main competitors?

Broad incumbents on record are Biocon, Celltrion, Stada Arzneimittel and Pharmstandard. Direct peers are BIOCAD, R-Pharm and Sarepta Therapeutics. Emerging players are Samsung Bioepis and Alvotech. Polpharma Biologics is listed as a regional player.

Does Generium have an API?

No public API is recorded for Generium.

What industry is Generium in?

Generium's product category is Biopharmaceutical Manufacturing (Biosimilars and Gene Therapy). Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UzdailyMBFITI and GENERIUM Sign Cooperation MemorandumMBFITI and Russian company GENERIUM signed a cooperation memorandum in biopharmaceuticals and biotechnology. The agreement covers scientific exchange, joint projects, and development of biological medicines and biotechnologies. Cooperation will include support for research and joint work on promising projects.UzdailyUzbekistan Studies Russia’s Private Medicine, Pharma ExperienceA delegation from Uzbekistan visited Russia to study the country's private healthcare sector and pharmaceutical industry, visiting facilities including the International Medical Cluster, several private clinics, and the biotech company GENERIUM. The delegation examined models for organizing medical care, innovative technologies, and business processes in the healthcare sector. The parties discussed prospects for technology transfer, localizing production of in-demand medicines in Uzbekistan, and creating joint research and production facilities.UzdailyUzbekistan and Generium Discuss Biopharma Joint ProjectsThe Director of Uzbekistan's Agency for the Development of the Pharmaceutical Industry, Abdulla Azizov, held negotiations with JSC Generium management during a working visit to Russia. The talks focused on biotechnology cooperation, technology transfer, joint investment projects, and developing modern biopharmaceutical manufacturing capabilities in Uzbekistan. Both parties noted that the agreements establish a foundation for bilateral cooperation and accelerated growth of biotechnological production in Uzbekistan.